Want investment and innovation? Call yourself a ‘biopharma’ firm
With consistent year-on-year growth of around 12%, biopharma is the ‘favored child’ of the drug industry, says BioPlan Associates’ Eric Langer. At the first BIOLive event at CPhI Worldwide in Madrid this week, Eric Langer, president and managing partner at BioPlan Associates, told delegates ...
Merck & Co. has ended the commercialization of Lusduna, a version of Sanofi’s Lantus (insulin glargine), and will pay Samsung Bioepis a ter ...
Compugen has gained access to top-selling programmed death-1 (PD-1) inhibitor Opdivo (nivolumab) through collaboration and a $12 million investme ...
Genmab says it chooses to outsource all its biomanufacturing having previously had its fingers burnt buying a facility in Minnesota, now owned by ...
Mundipharma acquires Cinfa; Sandoz resolves dispute with AbbVie; FDA favours Celltrion and Teva’s rituximab. Welcome to the heady world of bios ...
Recent Tweets
-
RT @Dan5tanton: @Merck drops Lantus biosimilar, blames pricing and production cost concerns. Pays Samsung Bioepis $155m in germinat… https://t.co/ggVpvgI6Sj
2 hours ago
-
@bmsnews invests in @CompugenInc , grants access to #Opdivo for combo trial https://t.co/GJuqhho8S0
2 hours ago
-
RT @Dan5tanton: Plant-based protein expression offers high yields and easy harvesting but has been held back by a lack of funding a… https://t.co/vMdKoziN7G
6 hours ago
-
#biosimilars round-up: Deal-breaking, approvals, and patents https://t.co/VUyrodqBjH
3 days ago
Trending
Analytical
Trends in Chemistry, Manufacturing, and Controls: Next-Generation Technologies and Product Modalities
Manufacturing
eBook: Scalable Cell-Based Immunotherapy Manufacture: A Comparison of Single-Use Agitated and Static Expansion Technologies
Analytical
Rapid Generation of High-Producing Clonal Cell Lines: Using FRET-Based Microfluidic Screening for Analysis, Sorting, Imaging, and Dispensing
Upstream Processing
Cell Culture Media: An Active Pharmaceutical Ingredient or Ancillary Material?